徳島大学 / 教育研究者総覧 --- 大谷環樹

専門分野

研究テーマ

著書・論文

学術論文(審査論文):

1.	Bollos Christine Anne Leah Locsin, Ryosuke Kasai, Hideki Otsuka, Youichi Otomi, Koji Yamaguchi, Tomomi Matsuura, Tamaki Otani, Takanori Bandoh, Yuya Ueki, Noritake Matsuda, Satoru Takashi, Shota Azane, Yamato Kunikane, Shoichiro Takao, Shusuke Yagi, Masataka Sata, Hitoshi Ikushima and Masafumi Harada : Ventilation/Perfusion Mismatch in Pulmonary Vein Stenosis Secondary to Atrial Fibrillation Ablation, Asia Oceania Journal of Nuclear Medicine & Biology, 13, 1, 62-69, 2024. (要約) We present two patients with a history of paroxysmal atrial fibrillation who developed pulmonary vein stenosis (PVS) following atrial fibrillation (AF) ablation. Case 1 involved a female patient in her 50s who was asymptomatic for pulmonary symptoms but was found to have a high degree of left superior PVS 15 months after AF ablation. This was demonstrated using contrast-enhanced computed tomography (CE-CT) and supported by findings of perfusion defects on ventilation-perfusion (V/Q) scan. Case 2 was a male patient in his 60s who developed progressive left superior PVS nine months after AF ablation, evidenced by serial CE-CT and V/Q scans. PVS is a rare but well-known complication of pulmonary vein ablation for the treatment of AF that can lead to severe complications if left untreated. V/Q scans effectively assess the functional significance of PVS by detecting abnormal blood flow segments. Although a V/Q mismatch characterized by reduced perfusion defects is more commonly used in evaluating pulmonary embolism, PVS should not be disregarded as a differential diagnosis. Few studies emphasize the utility of V/Q scans in managing PVS and highlight V/Q mismatch as a notable finding. This case report aimed to highlight their significance. (徳島大学機関リポジトリ) ● Metadata: 2012222 (出版サイトへのリンク) ● Publication site (DOI): 10.22038/AOJNMB.2024.79650.1561 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.22038/AOJNMB.2024.79650.1561 (徳島大学機関リポジトリ: 2012222, DOI: 10.22038/AOJNMB.2024.79650.1561)
2.	MATSUDA Noritake, Hideki Otsuka, Ryosuke Kasai, Tamaki Otani, BOLLOS CHRISTINE ANNE LEAH LOCSIN, Shota Azane, Yamato Kunikane, Youichi Otomi, UEKI Yuya, Mana Okabe, Masafumi Amano, Masanori Tamaki, Shu Wakino, Shoichiro Takao and Masafumi Harada : Quantitative evaluation of 67Gacitrate scintigraphy in the management of nephritis, Scientific Reports, 14, 16313, 16313, 2024. (要約) In Ga-citrate scintigraphy (Ga-S), visual assessment is used by evaluating renal-uptake comparison with liver and spine and is simple and objective. We adopted the standardized uptake value (SUV) for Ga-citrate and proposed two quantitative indices, active nephritis volume (ANV) and total nephritis uptake (TNU). This study clarified the utility of new Ga-S-based quantitative indices in nephritis management. Before SUV measurement, the Becquerel calibration factor of Ga-citrate was obtained using a phantom experiment. Seventy patients who underwent SPECT/CT imaging were studied. SUV, ANV, and TNU were calculated using a quantitative analysis software for bone SPECT. SUV, ANV, and TNU were analyzed using the (1) threshold method (set 40%) and constant-value method for (2) vertebral SUV, and (3) vertebral SUV. ROC analysis was used to evaluate SUV, ANV, and TNU diagnostic abilities to distinguish nephritis presence and absence as well as interstitial nephritis (IN) and non-IN. The area under the curve (AUC) for nephritis presence or absence had a good value (0.80) for SUV (1), ANV (3), and TNU (3). The AUC for differentiation between IN and non-IN groups had a good value (0.80) for SUV (1). Thus, the new Ga-S-based quantitative indices were useful to evaluate nephritis and distinguish IN and non-IN. (キーワード) Humans / 男性 (male) / 女性 (female) / Middle Aged / Gallium Radioisotopes / Aged / Gallium / Adult / Nephritis / Citrates / ROC Curve / Aged, 80 and over / Radiopharmaceuticals / Single Photon Emission Computed Tomography Computed Tomography (徳島大学機関リポジトリ) ● Metadata: 2012175 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-024-66823-2 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39009630 ● Search Scopus @ Elsevier (PMID): 39009630 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-024-66823-2 (徳島大学機関リポジトリ: 2012175, DOI: 10.1038/s41598-024-66823-2, PubMed: 39009630)
3.	Yuya Ueki, Hideki Otsuka, Tamaki Otani, Ryosuke Kasai, Youichi Otomi, Daiki Ikemitsu, Shota Azane, Yamato Kunikane, Takanori Bandoh, Noritake Matsuda, Yasuyuki Okada, Tetsuji Takayama and Masafumi Harada : Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors, Japanese Journal of Radiology, 42, 5, 519-535, 2024. (要約) Somatostatin receptor scintigraphy (SRS) using In-DTPA-DPhe-octreotide (pentetreotide) has become an integral part of neuroendocrine neoplasm management. The lack of precise quantification is a disadvantage of SRS. This study aimed to adapt the standardized uptake value (SUV) to SRS, establish the SUV range for physiological uptake in the liver, kidney, and spleen, and elucidate the utility of combined visual and quantitative SRS assessment for staging and restaging of neuroendocrine tumors (NETs). This study included 21 patients with NETs who underwent In-pentetreotide SRS. The SUV of physiological and pathological uptake was calculated using bone single-photon emission computed tomography (SPECT) quantitative analysis software (GI-BONE). For visual analysis, the primary and metastatic lesions were scored visually on planar and SPECT images using a five-point scale. We assessed the relationships between the SUVs of the liver, kidney, and spleen in the dual phase, and among quantitative indices, visual score, and pathological lesions classification. Sixty-three NEN lesions were evaluated. The mean ± standard deviation maximum SUVs (SUVmax) were liver: 4 h, 2.6 ± 1.0; 24 h, 2.2 ± 1.0; kidney: 4 h, 8.9 ± 1.8; 24 h, 7.0 ± 2.0; and spleen; 4 h, 11.3 ± 4.5; 24 h, 11.5 ± 7.6. Higher SUVmax was significantly associated with higher visual scores on dual-phase SPECT (4 h, p < 0.001; 24 h, p < 0.001) (4 h: scores 3 and 4, p < 0.05; scores 3 and 5: p < 0.01; scores 4 and 5: p < 0.01; 24 h: scores 3 and 4, p = 0.0748; scores 3 and 5: p < 0.01; scores 4 and 5: p < 0.01). We adapted the SUV to SRS and established the range of SUV for physiological uptake in the liver, kidney, and spleen. Combined visual and quantitative assessment is useful for imaging individual lesions in greater detail, and may serve as a new tumor marker of SRS for staging and restaging of NETs. (キーワード) Humans / Neuroendocrine Tumors / Male / Female / Middle Aged / Neoplasm Staging / Aged / Adult / Receptors, Somatostatin / Radiopharmaceuticals / Tomography, Emission-Computed, Single-Photon / Somatostatin / Retrospective Studies / Aged, 80 and over (徳島大学機関リポジトリ) ● Metadata: 2011702 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s11604-024-01529-z (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38345724 ● Search Scopus @ Elsevier (PMID): 38345724 ● Search Scopus @ Elsevier (DOI): 10.1007/s11604-024-01529-z (徳島大学機関リポジトリ: 2011702, DOI: 10.1007/s11604-024-01529-z, PubMed: 38345724)
4.	Noritake Matsuda, Hideki Otsuka, Tamaki Otani, Shota Azane, Yamato Kunikane, Yoichi Otomi, Yuya Ueki, Masahiro Kubota, Masafumi Amano, Shusuke Yagi, Masataka Sata and Masafumi Harada : New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy, Japanese Journal of Radiology, 41, 4, 428-436, 2023. (要約) Amyloid light chain (AL) and transthyretin (ATTR) are the major subtypes of cardiac amyloidosis (CA). Tc-pyrophosphate (PYP) scintigraphy is used to differentiate ATTR from other CA subtypes. We adapted the standardized uptake value (SUV) for Tc-PYP and proposed two quantitative indices, amyloid deposition volume (AmyDV) and total amyloid uptake (TAU). This study aimed to evaluate the utility of these quantitative indices in differentiating ATTR from non-ATTRs. Before the SUV measurement, the Becquerel calibration factor (BCF) of Tc was obtained by a phantom experiment. Thirty-two patients who had undergone hybrid SPECT/CT imaging 3 h after injection of Tc-PYP (370 MBq) were studied. CT attenuation correction for image reconstruction was applied in all. We calculated SUV, AmyDV, and TAU using a quantitative analysis software program for bone SPECT (GI-BONE) and analyzed AmyDV using two methods: threshold method (set 40%); and constant value method (average SUV of ribs). We assessed the diagnostic ability of heart-to-contralateral lung (H/CL) ratio, SUV, AmyDV, and TAU to differentiate ATTR from non-ATTR using receiver operating characteristic (ROC) analysis. Statistically significant differences in all quantitative indices were observed between ATTR and non-ATTR. The area under the curve of each quantitative index for discriminating between ATTR and non-ATTR were as follows: H/CL, 0.997; SUV, 0.953; SUV (M1), 0.964; SUV (M2), 0.969; AmyDV (M1), 0.875; AmyDV (M2), 0.974; and TAU, 0.974. The AmyDV (M2) had higher diagnostic ability than AmyDV (M1). Thus, TAU was calculated as AmyDV (M2) × SUV (M2). In the ROC curve, SUV, AmyDV, and TAU had almost the same diagnostic ability as H/CL in distinguishing ATTR from non-ATTRs. We propose two novel 3D-based quantitative parameters (AmyDV and TAU) that have almost equal ability to discriminate ATTR from non-ATTR. (徳島大学機関リポジトリ) ● Metadata: 2010702 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s11604-022-01364-0 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36449252 ● Summary page in Scopus @ Elsevier: 2-s2.0-85143121783 (徳島大学機関リポジトリ: 2010702, DOI: 10.1007/s11604-022-01364-0, PubMed: 36449252, Elsevier: Scopus)
5.	Tamaki Otani, Hideki Otsuka, Kou Matsushita, Yoichi Otomi, Yamato Kunikane, Shota Azane, Masafumi Amano, Masafumi Harada and Hirokazu Miyoshi : Effect of different examination conditions on image quality and quantitative value of amyloid positron emission tomography using F-flutemetamol., Annals of Nuclear Medicine, 35, 9, 1004-1014, 2021. (要約) The recommended start time for F-flutemetamol amyloid positron emission tomography (PET) examination is 60-120 min after F-flutemetamol injection, while an acquisition time of 10-30 min is generally recommended. We aimed to elucidate the effects of different examination conditions on image quality, diagnostic ability, and quantitative value of amyloid PET using F-flutemetamol. We acquired data on a Discovery PET/computed tomography 710 scanner using Hoffman brain and pillar phantoms with 20 MBq of F for 30 min. The images were reconstructed into 10-, 20-, and 30-min periods. The ordered subset-expectation maximization algorithm was used for image reconstruction, which uses a 2- or 4-mm Gaussian filter and a combination of iteration and subset numbers. The percentage contrast and coefficient of variation (CV; as the image noise) were used as physical evaluation indices for reconstructed images, and images with superior contrast and low image noise were selected for clinical evaluation. The imaging data of 15 symptomatic patients (n = 7 and n = 8 for positive and negative diagnoses of Alzheimer's disease, respectively) were reconstructed under the phantom study conditions. Radiographers visually evaluated and ranked the clinical images based on the overall contrast and image noise, and nuclear medicine specialists diagnosed Alzheimer's disease. We compared the standardized uptake value ratio (SUVR) obtained with different acquisition conditions. The basic study using the phantom revealed high convergence of contrast and image noise in five patterns of acquisition time and filter strengths. Regarding visual evaluation, the use of a 2-mm Gaussian filter caused difficulties in diagnosis because the brain parenchymal accumulation was mottled with high image noise. Differences in image quality and diagnostic ability due to different examination times were not significant. Differences in the SUVR were not significant in patients with a negative Alzheimer's disease diagnosis; in patients with a positive diagnosis, the SUVR showed significant fluctuation depending on the acquisition conditions. The differences in image quality and diagnostic performance due to the differences in 10-min acquisition time were not significant; however, of note, SUVR showed significant fluctuation depending on the acquisition conditions in patients diagnosed with Alzheimer's disease. (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12149-021-01634-3 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34046870 ● Search Scopus @ Elsevier (PMID): 34046870 ● Search Scopus @ Elsevier (DOI): 10.1007/s12149-021-01634-3 (DOI: 10.1007/s12149-021-01634-3, PubMed: 34046870)
6.	Ryota Bando, Hideki Otsuka, Tamaki Otani, Noritake Matsuda, Shota Azane, Yamato Kunikane, Yoichi Otomi, Wataru Sako, Yuishin Izumi and Masafumi Harada : A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography., Annals of Nuclear Medicine, 35, 4, 504-513, 2021. (要約) Dopamine transporter single-photon emission computed tomography (DAT SPECT) has been widely used to diagnose Parkinson syndrome. Using the standardized uptake value (SUV) of DAT SPECT, we propose "functional dopamine transporter volume (f-DTV)" as a new quantitative index to evaluate the three-dimensional volume of functional dopamine transporters and assess its diagnostic ability in differentiating dopaminergic neurodegenerative diseases (dNDD) from non-dNDD. Seventy-nine patients were enrolled (42 dNDD, 37 non-dNDD; 38 men; age 24-88 years). We analyzed seven quantitative indices. The specific binding ratio (SBR) was calculated using a program specialized for DAT SPECT (SBR_Bolt). The SUVmax, SUVpeak, and SUVmean were calculated using a quantification program for bone SPECT. SBR_SUV was calculated by dividing striatal SUVmean by the average of background SUVmean. The cutoff value of the active dopamine transporter level was examined using three methods (threshold of 40% of SUVmax, SUV 2, and SUV 3) to calculate the active dopamine transporter volume (ADV). The f-DTV was calculated by multiplying ADV and SUV. We assessed the correlations between SBR_Bolt and SBR_SUV, and compared the mean value of each index between the dNDD and non-dNDD groups. The abilities of SBR_Bolt, SBR_SUV, SUVmax, SUVpeak, SUVmean, ADV, and f-DTV in differentiating dNDD from non-dNDD were determined by the area under the receiver operating curve (AUC) generated by the receiver operating characteristics analysis. The SBR_Bolt and SBR_SUV highly correlated with each other (r = 0.71). The cutoff value of the active dopamine transporter level was determined as SUV 3. All seven quantitative indices showed lower values in the dNDD group than in the non-dNDD group, and the difference between the two groups was statistically significant (p < 0.05). Sensitivity, specificity, and AUC of f-DTV were slightly lower than those of SBR_Bolt (71%, 79%, and 0.81, respectively, for f-DTV, and 81%, 84%, 0.88, respectively, for SBR_Bolt). The difference in AUC between f-DTV and SBR_Bolt was not statistically significant. This study demonstrates the utility of f-DTV as a novel quantitative index for evaluating the three-dimensional volume of functional dopamine transporters, and that f-DTV has almost the same diagnostic ability to differentiate dNDD from non-dNDD using DAT SPECT. (キーワード) Adult / Aged / Aged, 80 and over / Biological Transport / Diagnosis, Differential / Dopamine Plasma Membrane Transport Proteins / 女性 (female) / Humans / Iodine Radioisotopes / 男性 (male) / Middle Aged / Nortropanes / パーキンソン病 (Parkinson's disease) / Phantoms, Imaging / ROC Curve / Retrospective Studies / Tomography, Emission-Computed, Single-Photon (徳島大学機関リポジトリ) ● Metadata: 2008753 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12149-021-01592-w (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33630226 ● Summary page in Scopus @ Elsevier: 2-s2.0-85101738030 (徳島大学機関リポジトリ: 2008753, DOI: 10.1007/s12149-021-01592-w, PubMed: 33630226, Elsevier: Scopus)
7.	Yumiko Miyatake, Yuna Mishima, Rie Tsutsumi, Tamaki Otani, Naoya Suemasa, Saeko Masumoto, Masashi Kuroda and Hiroshi Sakaue : Assessment of insulin resistance in the skeletal muscle of mice using positron emission tomography/computed tomography imaging., Biochemical and Biophysical Research Communications, 528, 3, 499-505, 2020. (要約) Measuring glucose uptake in the skeletal muscle in vivo is an effective method to determine glucose metabolism abnormalities as the skeletal muscle is the principal tissue responsible for glucose disposal and is a major site of peripheral insulin resistance. In this study, we investigated the pathological glucose metabolism dynamics of the skeletal muscle of C57BL/6J mice in a noninvasive and time-sequential manner using positron emission tomography/computed tomography (PET/CT), an imaging technique that uses radioactive substances to visualize and measure metabolic processes in the body, with [ (徳島大学機関リポジトリ) ● Metadata: 2011059 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.bbrc.2020.05.165 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32513534 ● Search Scopus @ Elsevier (PMID): 32513534 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbrc.2020.05.165 (徳島大学機関リポジトリ: 2011059, DOI: 10.1016/j.bbrc.2020.05.165, PubMed: 32513534)
8.	Mariko Aoyama, Hiromitsu Takizawa, Tamaki Otani, Seiya Inoue, Naoya Kawakita, Mitsuhiro Tsuboi, Yoshimi Bando, Hisanori Uehara, Kazuya Kondo and Akira Tangoku : Noninvasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using smallanimal FDGPET/CT, Oncology Reports, 44, 1709-1716, 2020. (徳島大学機関リポジトリ) ● Metadata: 2008265 (出版サイトへのリンク) ● Publication site (DOI): 10.3892/or.2020.7720 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.3892/or.2020.7720 (徳島大学機関リポジトリ: 2008265, DOI: 10.3892/or.2020.7720)
9.	Tamaki Otani, Kazuya Kondo, Hiromitsu Takizawa, Koichiro Kajiura, Haruhiko Fujino, Hideki Otsuka and Hirokazu Miyoshi : Noninvasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDGPET/CT and CT., Oncology Reports, 41, 1, 447-454, 2019. (要約) We established patient-like models of lung cancer metastasis by orthotopically implanting human non-small cell lung cancer cell lines into SCID mice. We evaluated the utilities of small-animal computed tomography (CT) and positron-emission tomography-computed tomography (PET/CT) in these models to non-invasively and repeatedly monitor the anticancer effects of cisplatin and erlotinib. We orthotopically implanted three non-small cell lung cancer cell lines, A549, FT821 and PC-9, into SCID mice. These mice were then divided into three groups: Control, cis-diamminedichloroplatinum (II) (CDDP) (7-mg/kg CDDP, single administration intraperitoneally), and erlotinib (25 mg/kg erlotinib/day, oral administration 5 days/week). After treatment initiation, we repeatedly performed PET/CT and CT measurements and assessed anticancer effects based on tumor volumes and FDG uptake. A549 tumors were not affected by CDDP or erlotinib. FT821 tumors were highly responsive to CDDP. PC-9 tumors, which have an epidermal growth factor receptor mutation, were highly responsive to erlotinib. Histological results and metastatic rates correlated with the anticancer effects shown by CT. In our orthotopic SCID mouse lung cancer models, 18FDG-PET/CT and CT imaging non-invasively and repeatedly monitored the efficacies of cisplatin and erlotinib against not only implanted tumors, but also mediastinal lymph node metastases. (キーワード) Animals / Carcinoma, Non-Small-Cell Lung / Cell Line, Tumor / Cisplatin / Erlotinib Hydrochloride / Fluorodeoxyglucose F18 / Humans / Lung Neoplasms / Lymph Nodes / Lymphatic Metastasis / 男性 (male) / Mice / Mice, SCID / Positron Emission Tomography Computed Tomography / Positron-Emission Tomography / Tomography, X-Ray Computed / Tumor Burden (出版サイトへのリンク) ● Publication site (DOI): 10.3892/or.2018.6818 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30365151 ● Summary page in Scopus @ Elsevier: 2-s2.0-85056802482 (DOI: 10.3892/or.2018.6818, PubMed: 30365151, Elsevier: Scopus)
10.	Hirokazu Miyoshi, Mitsunori Hiroura, Kazunori Tsujimoto, Namiko Irikura, Tamaki Otani and Yasuo Shinohara : Preparation of new scintillation imaging material composed of scintillator-silica fine powders and its imaging of tritium, Radiation Protection Dosimetry, 174, 4, 478-484, 2017. (要約) A new scintillation imaging material [scintillator-silica fine powder (FP)] was prepared using silica FPs and scintillator-encapsulating silica nanoparticles (NPs) (scintillator-silica NPs). The wt% values of scintillator-silica NPs on the scintillator-silica FPs were 38, 43, 36 and 44%. Scintillation images of 3H, 63Ni, 35S, 33P, 204Tl, 89Sr and 32P dropped on the scintillator-silica FPs were obtained at about 37 kBq per 0.1-10 µl with a charge-coupled device (CCD) imager for a 5 min exposure. In particular, high-intensity CCD images of 35S were selectively obtained using the 2.25, 4.77 and 10 µm silica FPs with scintillator-silica NPs owing to the residual S of dimethyl sulfoxide in the preparation. Scintillation images of 3H at 1670 ± 9 Bq/0.5 µl and 347 ± 6 Bq/0.5 µl dropped in a 2 mm hole on the scintillator-silica FPs (6.78 and 10 µm) were also obtained using the CCD imager for a 2 h exposure. (出版サイトへのリンク) ● Publication site (DOI): 10.1093/rpd/ncw251 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27664433 ● Search Scopus @ Elsevier (PMID): 27664433 ● Search Scopus @ Elsevier (DOI): 10.1093/rpd/ncw251 (DOI: 10.1093/rpd/ncw251, PubMed: 27664433)
11.	Hirokazu Miyoshi, Hitoshi Gotoh, Mitsunori Hiroura, Yusuke Yamanaka, Namiko Irikura, Tamaki Otani and Yuko Yamamoto : Enhancement of counting efciency for tritium using light-excited scintillator silica pellets, Journal of Radioanalytical and Nuclear Chemistry, 311, 3, 1991-1999, 2017. (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s10967-017-5185-2 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1007/s10967-017-5185-2 (DOI: 10.1007/s10967-017-5185-2)
12.	Koji Nakaya, Hideki Otsuka, Kazuya Kondo, Tamaki Otani and Motoi Nagata : Tumor growth-inhibitory effect of an angiotensin-converting enzyme inhibitor (captopril) in a lung cancer xenograft model analyzed using 18F-FDG-PET/CT., Nuclear Medicine Communications, 37, 2, 139-146, 2016. (要約) We administered an angiotensin-converting enzyme inhibitor (captopril) to mice implanted with a human lung adenocarcinoma epithelial cell line (A549 cells) and investigated the tumor growth-inhibitory effect of captopril from the viewpoint of glucose metabolism using (18)F-fluorodeoxyglucose ((18)F-FDG)-PET/CT. Subcutaneous implantation of A549 cells (1.9×10(6) cells) was carried out in the lower right flank of mice. Fifteen days after the transplantation of A549 cells, mice (six in each group) were treated with captopril (3.0 mg/mouse) or saline (1000 μl/mouse) for 5 days. We performed (18)F-FDG-PET/CT imaging of the mice before and after the treatment and evaluated the degree of (18)F-FDG accumulation in tumors. In both groups (the captopril-administrated and control groups), values for the metabolic tumor volume (MTV), maximum standardized uptake value, total lesion glycolysis, and tumor volume after treatment had a tendency to increase. However, tumor growth was suppressed in the captopril-administrated group compared with the control group. In terms of the growth rate, the MTV and tumor volume were significantly different (P<0.05). It was found that captopril exerted a potential tumor growth-inhibitory effect; this was because the captopril-administrated group showed low values of MTV, maximum standardized uptake value, total lesion glycolysis, and tumor volume in comparison with the control group. (出版サイトへのリンク) ● Publication site (DOI): 10.1097/MNM.0000000000000404 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26465803 ● Summary page in Scopus @ Elsevier: 2-s2.0-84953361815 (DOI: 10.1097/MNM.0000000000000404, PubMed: 26465803, Elsevier: Scopus)
13.	Maerjianghan Abuduli, Hirokazu Ohminami, Tamaki Otani, Hitoshi Kubo, Haruka Ueda, Yoshichika Kawai, Masashi Masuda, Hisami Okumura, Hiroshi Sakaue, Hironori Yamamoto, Eiji Takeda and Yutaka Taketani : Effects of dietary phosphate on glucose and lipid metabolism., American Journal of Physiology, Endocrinology and Metabolism, 310, 7, E526-E538, 2016. (要約) Recent epidemiological and animal studies have suggested that excess intake of phosphate (Pi) is a risk factor for the progression of chronic kidney disease and its cardiovascular complications. However, little is known about the impact of dietary high Pi intake on the development of metabolic disorders such as obesity and type II diabetes. In this study, we investigated the effects of dietary Pi on glucose and lipid metabolism in healthy rats. Male, 8-wk-old Sprague-Dawley rats were divided into 3 groups and given experimental diets containing varying amounts of Pi, i.e. 0.2% (low Pi, LP), 0.6% (control Pi, CP), and 1.2% (high Pi, HP). After 4 weeks, HP group showed lower visceral fat accumulation compared with other groups, accompanied by a low respiratory exchange ratio (VCO2/VO2) without alteration of locomotive activity. HP group had lower levels of plasma insulin and non-esterified fatty acids. In addition, HP group also showed suppressed expression of hepatic lipogenic genes including sterol regulatory element binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase, whereas there was no difference in hepatic fat oxidation among the groups. On the other hand, uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor gamma coactivator alpha (PGC1) expression were significantly increased in the brown adipose tissue (BAT) of HP group. Our data demonstrated that a high Pi diet can negatively regulate lipid synthesis in the liver, and increased mRNA expression related to lipid oxidation and UCP1 in BAT, thereby preventing visceral fat accumulation. Thus, dietary Pi is a novel metabolic regulator. (徳島大学機関リポジトリ) ● Metadata: 2003203 (出版サイトへのリンク) ● Publication site (DOI): 10.1152/ajpendo.00234.2015 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26786774 ● Search Scopus @ Elsevier (PMID): 26786774 ● Search Scopus @ Elsevier (DOI): 10.1152/ajpendo.00234.2015 (徳島大学機関リポジトリ: 2003203, DOI: 10.1152/ajpendo.00234.2015, PubMed: 26786774)
14.	Tamaki Otani, Hideki Otsuka, Kazuya Kondo, Hiromitsu Takizawa, Motoi Nagata, Mina Kishida and Hirokazu Miyoshi : Utility of respiratory-gated small-animal PET/CT in the chronologic evaluation of an orthotopic lung cancer transplantation mouse model., Radiological Physics and Technology, 8, 2, 266-277, 2015. (要約) Our aim in this study was to clarify the effects of respiratory-gated PET in the evaluation of lung cancer according to the (18)F-FDG uptake in an orthotopic transplantation mouse model. We created such a model, and we performed PET/CT. The mice were divided into two groups according to tumor volume: a small-tumor group (<20 mm(3)) and a large-tumor group (>20 mm(3)). We reconstructed the following conditions based on list-mode data: non-gated (3D) images and gated (4D) images, divided based on the respiratory cycle (expiration phase, stable phase, and inspiration phase). We calculated the maximum standardized uptake values (SUVmax) in each phase. We used the % difference [= (4D SUVmax - 3D SUVmax)/3D PET SUVmax × 100 (%)] to evaluate the differences in the 4D SUVmax and 3D SUVmax. The 4D SUVmax values were significantly higher than the 3D SUVmax, regardless of the tumor size. The % difference for the small tumors was greater than that for the large tumors, and it was highest in the stable phase. We conclude that the SUVmax in the stable phase under respiratory-gated PET are the most reliable. The SUVmax observed under non-gated PET are considered to be more frequently underestimated in cases involving small tumors than in those involving large tumors. In the chronologic study evaluating the time course of tumor development, the size of the tumor is small in early stage, and respiratory-gated PET is effective in reducing the underestimation of such tumors caused by respiratory motion. (徳島大学機関リポジトリ) ● Metadata: 2002935 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12194-015-0316-3 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25921487 ● Summary page in Scopus @ Elsevier: 2-s2.0-84937518832 (徳島大学機関リポジトリ: 2002935, DOI: 10.1007/s12194-015-0316-3, PubMed: 25921487, Elsevier: Scopus)
15.	Hirokazu Miyoshi, Tamaki Otani and Namiko Irikura : In situ 18F-gamma-ray induced Ag nanoparticle formation in the presence of SiO2 nanoparticles under air, Journal of Radioanalytical and Nuclear Chemistry, 302, 3, 1177-1183, 2014. (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s10967-014-3359-8 (文献検索サイトへのリンク) ● Summary page in Scopus @ Elsevier: 2-s2.0-84919413696 (DOI: 10.1007/s10967-014-3359-8, Elsevier: Scopus)
16.	Mohamed Mokhtar, Kazuya Kondo, Hiromitsu Takizawa, Tamaki Otani, Hideki Otsuka, Hitoshi Kubo, Koichiro Kajiura, Yasushi Nakagawa, Yukikiyo Kawakami, Mitsuteru Yoshida, Haruhiko Fujino, Shoji Sakiyama and Akira Tangoku : Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [18F] FDG PET-CT., Oncology Reports, 31, 5, 2007-2014, 2014. (要約) Positron emission tomography-computed tomography (PET-CT) with [18F] fluorodeoxyglucose (FDG) has recently been applied for evaluating tumor response to anticancer therapy. The aim of the present study was to evaluate the utility of FDG PET-CT in monitoring non-invasively and repeatedly the inhibitory effect of cisplatin (CDDP) on an orthotopic lung cancer model. Validation of in vivo FDG uptake in human lung cancer Ma44-3 cell line in an orthotopic SCID mouse model was carried out. Next, we assessed the use of FDG PET-CT to monitor the response of orthotopic lung cancer to the anticancer effect of CDDP. SCID mice were divided into the CDDP group (7 mg/kg single dose intraperitoneally) and the control group. Tumor volume and maximal standardized uptake value (SUV max) were calculated for all mice. All mice were sacrificed for histopathologic analysis. Validation of FDG PET-CT showed that tumor volume and SUV max were significantly correlated with postmortem tumor length measured in specimens (P=0.023) and (P=0.012), respectively, and there was a significant correlation between SUV max and tumor volume (P=0.048). Response monitoring showed that significant growth inhibition by CDDP in the form of SUV max of the CDDP group was significantly lower than that of the control group on day 8 (P=0.02) and on day 13 (P=0.003). Tumor volume of the CDDP group was significantly lower than that of the control group on day 13 (P=0.03). The present study supports using FDG PET-CT in monitoring tumor progression and therapeutic response of lung cancer in an orthotopic model non-invasively and repeatedly. (キーワード) Animals / Antineoplastic Agents / Carcinoma, Non-Small-Cell Lung / Cell Line, Tumor / Cisplatin / Fluorodeoxyglucose F18 / Humans / Lung Neoplasms / Male / Mice / Mice, SCID / Multimodal Imaging / Positron-Emission Tomography / Tomography, X-Ray Computed / Tumor Burden (出版サイトへのリンク) ● Publication site (DOI): 10.3892/or.2014.3056 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24604559 ● Summary page in Scopus @ Elsevier: 2-s2.0-84898640682 (DOI: 10.3892/or.2014.3056, PubMed: 24604559, Elsevier: Scopus)
17.	Hitoshi Kubo, Tamaki Otani, Hideki Otsuka and Masafumi Harada : The impact of self-shielded cyclotron operation on small-animal PET/CT equipment installed nearby, on the floor just above., The Journal of Medical Investigation : JMI, 61, 1-2, 46-52, 2014. (要約) The purpose of this study was to evaluate the impact of a cyclotron on small-animal PET equipment installed directly above the cyclotron. The cyclotron equipment was HM-12, which has two targets, and the PET/CT equipment was Inveon. The equipment was installed in conformity to Japanese law and regulations. Before installation of the PET/CT equipment, the radiation dose, radio waves, and static and fluctuating magnetic fields were measured at the position where it would be placed, both when the cyclotron was in use and when it was not in use. After installation of the PET/CT, natural background and emission counts were measured at the same place under the same conditions. An increase of radiation dose was observed when the target nearest the PET equipment was used. There were no distinct effects of radio waves or static and fluctuating magnetic fields. A significant increase of emission counts, approximately 300 cpm, was observed when the nearest target was used. Though radio waves and static and fluctuating magnetic fields generated by running cyclotron had no influence, a significant increase in emission count was observed. Careful attention should be paid to this influence when very low-radioactivity PET measurements are done. (キーワード) Animals / Cyclotrons / Equipment Failure / 日本 (Japan) / Magnetic Fields / Positron-Emission Tomography / Radiation Dosage / Radio Waves / Static Electricity / Tomography, X-Ray Computed (徳島大学機関リポジトリ) ● Metadata: 2002768 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.61.46 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24705748 ● Search Scopus @ Elsevier (PMID): 24705748 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.61.46 (徳島大学機関リポジトリ: 2002768, DOI: 10.2152/jmi.61.46, PubMed: 24705748)

国際会議:

1.	Tamaki Otani, Hitoshi Ikushima, Yoshimi Bando, Kenmei Kuwahara, Hideki Otsuka, Kazuya Kondo and Hirokazu Miyoshi : Efficacy of 18F-fluorothymidine and 18F-fluorodeoxyglucose Positron Emission Tomography in Determining a Radiotherapy Effect., Annual Congress of the European Association of Nuclear Medicine, Oct. 2021.
2.	Tamaki Otani, Hideki Otsuka, Koh Matsushita, 音見陽一, Yamato Kunikane, Shota Azane and Hirokazu Miyoshi : Possibility of Shortening Examination Time in Amyloid PET using 18F-Flutemetamol., Society of Nuclear Medicine and Molecular Imaging 2020 annual meeting, Jul. 2020.
3.	Tamaki Otani, Kazuya Kondo, Hiromitsu Takizawa, Koichiro Kajiura, Fujino Haruhiko and Hideki Otsuka : Non-Invasive Assessment of Cisplatin and Erlotinib Efficacy in Lung Cancer by Monitoring an Orthotopic SCID Mouse Model with Computed Tomography, 16th World Conference on Lung Cancer, Sep. 2015.
4.	Hiromitsu Takizawa, Kazuya Kondo, Mitsuhiro Tsuboi, Koichiro Kajiura, Tamaki Otani, Hiroaki Toba, Yukikiyo Kawakami, Shoji Sakiyama and Akira Tangoku : Mini OralComputed Tomography Lymphography by Transbronchial Injection of Iopamidol for Preoperative, 16th World Conference on Lung Cancer, Sep. 2015.
5.	Abuduli Maerjianghan, Ohminami Hirokazu, Tamaki Otani, Kubo Hiroshi, Ueda Haruka, Eiji Takeda and Yutaka Taketani : Effect of Dietary Phosphate on Glucose Metabolism by 18F-FDG PET/CT in Rats, 75th Scientific Sessions, American Diabetes Association, Boston Convenstion and Exhibition Center, Boston MA, June 5-9, 2015, Jun. 2015.
6.	Hirokazu Miyoshi, Mitsunori Hiroura, Kazunori Tshuji, Namiko Irikura and Tamaki Otani : Newscintillation imaging material composed of fine silica powder for tritium detection, 15th International Congress of Radiation Research (ICRR 2015), Kyoto, May 2015.
7.	Tamaki Otani, Hideki Otsuka, Kazuya Kondo, Hiromitsu Takizawa and Nagata Motoi : Utility of respiratory-gated PET/CT in the chronological evaluation of an orthotopic lung cancer transplantation mouse model, Annual Congress of the European Association of Nuclear Medicine, Oct. 2014.

国内講演発表:

1.	板東孝典, 笠井亮佑, 大谷環樹, 長尾沙奈, 阿實翔太, 高志智, 国金大和, 音見暢一, 大塚秀樹 : ペプチド受容体放射性核種療法後後のシンチグラフィ定量化と視覚スコアによる治療効果評価, 第37回日本核医学技術学会中国・四国地方会, 2025年6月.
2.	板東孝典, 笠井亮佑, 大谷環樹, 長尾沙奈, 阿實翔太, 音見暢一, 大塚秀樹 : Attempt to evaluate efficiency of Lutetium treatment using scintigraphy after peptide receptor radionuclide therapy, 第84回日本放射線技術学会総会学術大会, 2025年4月.
3.	川端悠加, 笠井亮佑, 大谷環樹, 松田憲武, 板東孝典, 国金大和, 大塚秀樹 : Influence of attenuation correction using CT for cardiac SPECT/CT: A study of indicators for cardiac function, 第84回日本放射線技術学会総会学術大会, 2025年4月.
4.	川端悠加, 笠井亮佑, 大谷環樹, 松田憲武, 板東孝典, 国金大和, 大塚秀樹 : Influence of attenuation correction using CT for cardiac SPECT/CT: A study of indicators for heart accumulation, 第84回日本放射線技術学会総会学術大会, 2025年4月.
5.	木曾由梨香, 福田翔一郎, 向井英史, 田原強, 大谷環樹, 毛利浩太, 北原育美, 松尾礼子, 桑原宏哉, 永田哲也, 濱本英利, 石田竜弘, 横田隆徳, 金沢貴憲 : ヘテロ二本鎖核酸のNose-to-Brainデリバリーに対するNose-to-Brain送達ナノ粒子とイオン液体の有用性評価, 日本薬学会第145年会, 2025年3月.
6.	音見暢一, 板東孝典, 大塚秀樹, 笠井亮佑, 大谷環樹, 国金大和, 岡田直子, 松下知樹, 川中崇, 新家崇義, 原田雅史 : 徳島大学病院におけるペプチド受容体放射性核種療法の経験, 第64回日本核医学会学術総会/第44回日本核医学技術学会総会学術大会, 2024年11月.
7.	松田憲武, 笠井亮佑, 大塚秀樹, 大谷環樹, 高志智, 国金大和 : 最適輸送理論を用いたSPECT/CT における減弱補正の検討, 第20回中四国放射線医療技術フォーラム CSFRT2024, 2024年10月.
8.	板東孝典, 音見暢一, 笠井亮佑, 大谷環樹, 松田憲武, 新家崇義, 国金大和, 阿實翔太, 大塚秀樹, 原田雅史 : 123I-MIBGを用いた副腎髄質シンチグラフィ定量評価の試み, 第5回日本核医学会中国・四国支部会, 2024年7月.
9.	松田憲武, 笠井亮佑, 大塚秀樹, 大谷環樹, 国金大和 : 最適輸送理論による減弱補正の初期検討, 日本核医学技術学会, 2024年6月. (要約) 【目的】 CTAC(CTbasedattenuationcorrection)は核医学領域で最も一般的に利用されている補正法であるが，CT 撮影による被ばくの問題がある.近年，深層学習を使用した減弱補正法も考案されているが，学習に必要なデータセット作成の課題や，学習・実装のコストから問題点も多い.そこで，減弱補正に最適輸送理論に基づくドメイン適応を応用し，最適輸送減弱補正(OTAC: optimal transportAC) 法を提案する.最適輸送は確率分布を比較するツールとして知られ，機械学習の評価関数として広く利用されている.OTAC では，CTAC による補正後の一対の画像から，色相変換の手続きにより，補正後のドメインに適応し，マッピング推定を行う.すなわち，最適輸送による原理を用いることで，二つの画像のピクセルの対応関係を介した色相変換により，画像の形態は保持したまま，最適な画素値へのマッピングの実現が期待できる.本研究の目的は， OTAC を提案すること，およびその有効性を確認することである. 【方法】 99mTc を封入した円柱ファントムの SPECT 画像の CTAC による補正前後の画像ペアを用いた.最適輸送を使用し，輸送元の各ピクセルを輸送先の画素値に輸送コストの最小化によるマッピングをすることで，画素値の差の総和が最小になるように変換した.得られた最適輸送による減弱補正(OTAC)画像と CTAC 画像の視覚および，取得画像の濃度プロファイルによって提案法の性能評価を行った. 【結果】視覚的な結果および濃度プロファイルの結果から，OTAC は CTAC と同程度の性能を有していることが分かった. 【結論】最適輸送を用いた減弱補正を提案し，円柱ファントム画像において CTAC と同程度の結果が得られた.本手法では，減弱補正のための CT 撮影が不要であり，被曝低減を導くことができる.さらに深層学習のような大量の学習画像や実装コストも不要であり，結果も深層学習より高速に得られた.
10.	板東孝典, 笠井亮佑, 大谷環樹, 長尾沙奈, 松田憲武, 高志智, 阿實翔太, 大塚秀樹 : Attempt at quantitative evaluation using lutetium scintigraphy after peptide receptor radionuclide therapy, 第80回日本放射線技術学会総会学術大会, 2024年4月.
11.	BOLLOS CHRISTINE ANNE LEAH LOCSIN, Ryosuke Kasai, Hideki Otsuka, Youichi Otomi, Tomomi Matsuura, Tamaki Otani, BANDOH Takanori, UEKI Yuya, MATSUDA Noritake, 高志智, Shota Azane, Yamato Kunikane, Shoichiro Takao, Shusuke Yagi, Masataka Sata, Hitoshi Ikushima and Masafumi Harada : Ventilation/Perfusion Mismatch in Pulmonary Vein Stenosis After Atrial Fibrillation Ablation, 第268回徳島医学会学術集会, Mar. 2024.
12.	川端悠加, 笠井亮佑, 大谷環樹, 板東孝典, 松田憲武, 阿實翔太, 高志智, 国金大和, 天野雅史, 大塚秀樹 : 心臓サルコイドーシスを対象とした画像検査 ∼ 18F-FDG PET の有用性を中心に∼, 第19回中四国放射線医療技術フォーラム CSFRT2023, 2023年11月.
13.	大谷環樹, 三好弘一, 国金大和, 阿實翔太 : 陽電子断層撮像装置の経年変化による定量性変動, 第4回日本保健物理学会・放射線安全管理学会合同大会, 2022年11月.
14.	梶野晃未, 生島仁史, 佐々木幹治, 大谷環樹, 山下理子, 芳賀昭弘 : 放射線治療効果を早期に検出できるRadiomics特徴量の探索, 日本放射線腫瘍学会第35回学術大会, 2022年11月.
15.	三好弘一, 中村真美, 大谷環樹, 堀川秀昌 : シンチレーションペーパーの放射能測定紙としての応用, 第3回日本放射線安全管理学会・日本保健物理学会合同大会Web開催, 2021年12月.
16.	生島仁史, 大谷環樹, 大塚秀樹, 川中崇, 久保亜貴子, 外磯千智 : 放射線治療における18F-3'-deoxy-3'-fluorothymidine の有用性, 第134回日本医学放射線学会中国四国地方会, 2021年6月.
17.	三島優奈, 堤理恵, 大谷環樹, 原加奈子, 藤本紗織, 黒田雅士, 阪上浩 : PET/CTを用いたマウス骨格筋インスリン抵抗性の評価, 第41回日本肥満学会, 2021年3月.
18.	堀川秀昌, 桑原義典, 合田康代, 安井栄梨, 大谷環樹, 三好弘一 : 非密封放射性同位元素の使用施設におけるより良い放射線安全管理の追求, 第19回日本放射線安全管理学会学術大会(Web開催), 2020年12月.
19.	三島優奈, 堤理恵, 黒田雅士, 阪上浩, 大谷環樹 : PET/CTを用いたマウス骨格筋インスリン抵抗性の評価, 四国医学雑誌, 76, 5-6, 342, 2020年12月. (キーワード) インスリン抵抗性(実験的) 骨格筋(X線診断,放射性核種診断) *PET-CT検査マウス動物
20.	大谷環樹, 生島仁史, 坂東良美, 大塚秀樹, 近藤和也, 三好弘一 : 放射線治療効果判定における18F-FLT PETの有効性の検討, 第60回日本核医学学術総会, 2020年11月.
21.	吉田光輝, 近藤和也, 大谷環樹, 小川博久, 宮本直輝, 竹原恵美, 髙嶋美佳, 松本大資, 河北直也, 坪井光弘, 鳥羽博明, 川上行奎, 滝沢宏光, 丹黒章 : 呼吸器外科の癌免疫療法研究-CMT167マウス肺癌細胞株同所移植モデルマウスの確立に向けて-, 第37回日本呼吸器外科学会学術集会(Web開催), 2020年9月.
22.	徳里望, 阪上浩, 堤理恵, 黒田雅士, 升本早枝子, 原加奈子, 堤理恵, 三島優奈, 松本裕華, 黒田雅士, 大谷環樹, 阪上浩 : PET/CTを用いた代謝性疾患モデルマウス骨格筋糖取り込みの評価, 糖尿病, 63, 9, 649, 2020年9月. (キーワード) Catechin 肥満(実験的) Biflavonoids Proanthocyanidins 認知機能低下(実験的) 消化管微生物叢 Procyanidin マウス動物 / 高インスリン症(実験的) 疾患モデル(動物) 骨格筋(X線診断,放射性核種診断) Fluorodeoxyglucose F18(診断的利用) PET-CT検査マウス動物オス
23.	大谷環樹, 大塚秀樹, 国金大和, 阿實翔太, 藤田明彦, 天野雅史, 福永有希子, 三好弘一 : PET, 第76回日本放射線技術学会総会学術大会, 2020年5月.
24.	徳里望, 阪上浩, 堤理恵, 黒田雅士, 升本早枝子, 三島優奈, 堤理恵, 松本裕華, 原加奈子, 大谷環樹, 上嶋菜々子, 神田彩恵, 黒田雅士, 阪上浩 : 廃用性筋萎縮モデルにおける骨格筋・肝代謝動態の連関による生体機能制御, 日本病態栄養学会誌, 23, Suppl., S-54, 2020年1月. (キーワード) Catechin 肥満(実験的) Biflavonoids Proanthocyanidins 認知機能低下(実験的) 消化管微生物叢 Procyanidin マウス動物 / 遺伝子発現エネルギー代謝筋萎縮症(実験的) 骨格筋糖代謝廃用症候群(実験的) Large Neutral Amino Acid-Transporter 1 マウス動物
25.	三島優奈, 堤理恵, 松本裕華, 原加奈子, 大谷環樹, 上嶋菜々子, 神田彩恵, 黒田雅士, 阪上浩 : 廃用性筋萎縮モデルにおける骨格筋・艦隊者動態の連関による生体機能制御, 第23回日本病態栄養学会年次学術集会, 2020年1月.
26.	三好弘一, 大谷環樹, 桑原義典, 堀川秀昌, 合田康代, 安井栄梨 : 学内の放射線安全管理体制についての考察, 第2回放射線安全管理学会・日本保健物理学会合同大会, 2019年12月.
27.	大谷環樹, 草壁翔太, 三好弘一, 国金大和 : サイクロトロン施設における標識合成設備と排気放射能濃度の関係, 第2回放射線安全管理学会・日本保健物理学会合同大会, 2019年12月.
28.	三好弘一, 湯本明, 中村真美, 伊月義則, 吉岡歩美, 大谷環樹 : シンチレーションペーパーのふき取り効率, 第2回日本放射線安全管理学会・日本保健物理学会合同大会, 2019年12月.
29.	三島優奈, 堤理恵, 宮武由実子, 末政直哉, 大谷環樹, 兒玉直子, 丹波洋介, 黒田雅士, 升本早枝子, 阪上浩 : PET/CTを用いた代謝異常時の骨格筋における糖取り込みの測定, 第62回日本糖尿病学会, 2019年5月.
30.	大谷環樹, 三好弘一, 草壁翔太 : 自己遮蔽型サイクロトロンの運転時間と放射化物の関係性, 日本放射線安全管理学会第17回学術大会, 2018年12月.
31.	大谷環樹, 大塚秀樹, 国金大和, 高志智, 板東良太, 藤田明彦, 天野雅史, 福永有希子, 阿實翔太, 三好弘一 : 2. Ra-223イメージングにおける最適測定条件の検討, 第38回日本核医学技術学会総会学術大会, 2018年11月.
32.	大谷環樹, 三好弘一, 藤田明彦, 天野雅史, 国金大和, 福永有希子, 高志智, 坂東良太 : 放射線検出モジュールC12137を用いたRa-223γ(X)線スペクトル解析, 日本放射線安全管理学会第16回学術大会, 2017年6月.
33.	桑原知彦, 三好弘一, 山下陽子, 黒田トクエ, 入倉奈美子, 桑原義典, 安井栄梨, 合田康代, 大谷環樹 : RI施設の排風量を担保するための簡易風量計によるドラフト風量随時測定法の検討, 日本放射線安全管理学会第16回学術大会, 2017年6月.
34.	三好弘一, 中村真美, 合田康代, 安井栄梨, 大谷環樹, 入倉奈美子, 桑原義典 : 放射線業務従事者の放射線安全の理解度とヒヤリとした事例の分析, 日本放射線安全管理学会第15回学術大会(岡山大学), 2016年12月.
35.	山下陽子, 黒田トクエ, 桑原知彦, 入倉奈美子, 安井栄梨, 桑原義典, 合田康代, 大谷環樹, 三好弘一 : 非密封RI施設における排気時間の再考, 日本放射線安全管理学会第15回学術大会(岡山大学), 2016年12月.
36.	大谷環樹, 大塚秀樹, 三好弘一, 桑原義典, 入倉奈美子 : 動物PET計測において遮蔽体が散乱係数に与える影響, 日本放射線安全管理学会第15回学術大会(岡山大学), 2016年12月.
37.	黒田トクエ, 山下陽子, 桑原知彦, 入倉奈美子, 安井栄梨, 桑原義典, 合田康代, 大谷環樹, 三好弘一 : RI施設管理の自己点検評価への新しい試み, 平成28年度放射線安全取扱部会年次大会(鎌倉), 2016年11月.
38.	三好弘一, 庄野正行, 大谷環樹 : 5-FU-マルトールナノ粒子複合体の5-FU放出機構, 2016年日本化学会中国四国支部大会, 72, 2016年11月.
39.	三好弘一, 庄野正行, 今川慎吾, 大谷環樹, 倉科昌, 金崎英二 : 細胞膜吸着性と徐放出性を有する新規マルトール-シリカナノ粒子複合体の調製, 2015日本化学会中国四国支部大会, 2015年11月.
40.	Abuduli Maerjianghan, 大南博和, 阪上浩, 大谷環樹, 上田遥香, 武田英二, 竹谷豊 : 食事性のリンが糖代謝に及ぼす影響:PET/CT用いた解析, 第36回日本肥満学会，名古屋国際会議場，愛知県名古屋市，2015年10月2日~3日, 2015年10月.
41.	三好弘一, 大谷環樹, 桑原義典, 入倉奈美子, 合田康代, 安井栄梨, 永田基 : 放射線教育スライドのパッケージ化とその効果, 日本放射線安全管理学会第13回学術大会, 151, 2014年12月.
42.	大谷環樹, 三好弘一, 永田基, 大塚秀樹 : Daily-QCから得られる物理的指標値からみるPET装置の経年変化, 日本放射線安全管理学会第13回学術大会, 128, 2014年12月.
43.	大谷環樹, 大塚秀樹, 永田基 : 肺癌同所移植モデルマウスの呼吸同期PET/CT測定の有用性の検討, 第54回日本核医学学術総会, 2014年11月.
44.	三好弘一, 大谷環樹, 永田基, 入倉奈美子 : 18-Fを用いたシリカナノ粒子水分散液における放射線化学反応の試み, 日本放射線安全管理学会第12回学術大会, 2013年11月.
45.	三好弘一, 安井栄梨, 入倉奈美子, 大谷環樹, 永田基 : 土壌中の放射性セシウムの加水による放射能分布変化とその分析, 日本放射線安全管理学会第12回学術大会, 2013年11月.
46.	大谷環樹, 大塚秀樹, 近藤和也, 滝沢宏光, 三好弘一 : 肺癌同所移植モデルマウスの18F-FDG PET/CTイメージング, 日本放射線安全管理学会第12回学術大会, 2013年11月.
47.	滝沢宏光, 近藤和也, 大谷環樹, 大塚秀樹, 坪井光弘, 梶浦耕一郎, 中川靖士, 吉田光輝, 川上行奎, 先山正二, 丹黒章 : PET/CTによるヒト肺癌細胞株肺移植モデルマウスの腫瘍評価, 第54回日本肺癌学会総会, 2013年11月.
48.	岸田弥奈, 大谷環樹, 大塚秀樹, 近藤和也 : 肺癌同所移植モデルマウスの経時的測定におけるPET呼吸同期収集がSUVに与える影響について, 中四国放射線技術ファーラム2013, 2013年11月.
49.	大谷環樹, 大塚秀樹 : 動物用PET/CTを用いた乳癌骨転移モデルマウスのゾレドロン酸による治療効果評価法の検討, 第53回日本核医学学術総会, 2013年11月.

その他・研究会:

1.	田原強, 篠﨑千穂, 吉丸哲郎, 毛利浩太, 傳田将也, 大谷環樹, 片桐豊雅, 大髙章, 向井英史, 崔翼龍 : PETを用いた脂質化抗がんペプチドの動態解析, 日本分子イメージング学会, 2024年5月.

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

人工知能を用いた心臓核医学画像生成モデルと新たな非CT吸収補正再構成法の開発 (研究課題/領域番号: 25K11010 )
核医学内用療法におけるシクロデキストリンを用いた集積促進効果に関する検討 (研究課題/領域番号: 25K10963 )
食品添加物で放射性核種の生体内動態を制御して被ばくのリスクを最小にする (研究課題/領域番号: 25K00736 )
レディオミクス画像解析に基づく新たな放射線治療戦略構築に資する研究 (研究課題/領域番号: 23K07158 )
食品添加物で放射性核種の体内移行を阻害・促進させる (研究課題/領域番号: 23K22215 )
放射線治療効果を高精度に予測する分子イメージングレディオミクスモデルの開発 (研究課題/領域番号: 20K07698 )
11C-Erlotinibを用いたエルロチニブ抗腫瘍効果予測に関する研究 (研究課題/領域番号: 15K19797 )
研究者番号（40709557）による検索

助教 : 大谷環樹

研究活動

専門分野

研究テーマ

著書・論文

学術論文(審査論文):

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

助教 : 大谷 環樹

研究活動

専門分野

研究テーマ

著書・論文

学術論文(審査論文):

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

助教 : 大谷環樹